Literature DB >> 21459615

Microembolic signals in patients with cryptogenic stroke with or without patent foramen ovale.

Abdolhamid Shariat1, Ehsan Yaghoubi, Reza Nemati, Ali Reza Moaref, Kamran Aghasadeghi, Afshin Borhani Haghighi.   

Abstract

BACKGROUND: To evaluate the incidence, frequency, and contributing factors of microembolic signals (MESs) in patients with cryptogenic stroke with or without patent foramen ovale (PFO).
METHODS: Transcranial Doppler monitoring for MESs detection was performed for 62 patients with acute cryptogenic stroke with PFO (PFO(+)) and 34 patients with acute cryptogenic stroke without PFO (PFO(-)).
RESULTS: The incidence of MESs was not significantly higher in PFO(+) patients (17/62, 27.4%) in comparison to PFO(-) patients (6/34, 17.6%; odds ratio 1.76, 95% confidence interval 0.62-5.00; P = .327). The frequency of MESs in PFO(+) patients was statistically higher than that of PFO(-) patients (0.70 ± 1.47 v 0.23 ± 0.55; P = .026). MESs was presented with higher incidence in a subgroup of patients suffering from both patent foramen ovale and atrial septal aneurysm (P = .044).
CONCLUSIONS: The likelihood of PFO as a source of MESs is higher when associated with atrial septal aneurysm.
Copyright © 2012 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21459615     DOI: 10.1016/j.jstrokecerebrovasdis.2011.02.015

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  2 in total

1.  Unusual neurologic manifestations of a patient with cyanotic congenital heart disease after phlebotomy.

Authors:  Hooman Salimipour; Somayeh Mehdizadeh; Reza Nemati; Mohamad Reza Pourbehi; Gholam Reza Pourbehi; Majid Assadi
Journal:  Case Rep Neurol Med       Date:  2015-04-02

2.  Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: A randomized clinical trial.

Authors:  Abdolhamid Shariat; Ehsan Yaghoubi; Mohsen Farazdaghi; Kamran Aghasadeghi; Afshin Borhani Haghighi
Journal:  J Res Med Sci       Date:  2013-02       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.